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Abstract
Background & Aims:	 Insulin	resistance	is	a	risk	marker	for	non-	alcoholic	fatty	liver	
disease,	and	a	risk	factor	for	liver	disease	progression.	We	assessed	temporal	trajec-
tories	 of	 insulin	 resistance	 and	 β-	cell	 response	 to	 serum	 glucose	 concentration	
throughout	adulthood	and	their	association	with	diabetes	risk	in	non-	alcoholic	fatty	
liver disease.
Methods:	 Three	 thousand	 and	 sixty	 participants	 from	 Coronary	 Artery	 Risk	
Development	 in	 Young	 Adults,	 a	 prospective	 bi-	racial	 cohort	 of	 adults	 age	 18-	
30	years	at	baseline	(1985-	1986;	Y0)	who	completed	up	to	5	exams	over	25	years	and	
had	 fasting	 insulin	 and	 glucose	measurement	were	 included.	At	Y25	 (2010-	2011),	
non-	alcoholic	fatty	liver	disease	was	assessed	by	noncontrast	computed	tomography	
after	exclusion	of	other	liver	fat	causes.	Latent	mixture	modelling	identified	25-	year	
trajectories	in	homeostatic	model	assessment	insulin	resistance	and	β-	cell	response	
homeostatic	model	assessment-	β.
Results:	 Three	 distinct	 trajectories	 were	 identified,	 separately,	 for	 homeostatic	
model	assessment	 insulin	resistance	(low-	stable	[47%];	moderate-	increasing	[42%];	
and	 high-	increasing	 [12%])	 and	 homeostatic	 model	 assessment-	β	 (low-	decreasing	
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1  | INTRODUC TION
Non-	alcoholic	 fatty	 liver	disease	 (NAFLD)	 is	considered	 the	hepatic	
manifestation	of	the	metabolic	syndrome	with	a	well-	established	as-
sociation	with	insulin	resistance	(IR).	NAFLD	prevalence	approaches	
70%	among	persons	with	type	2	diabetes	mellitus	(T2DM).1	However,	
NAFLD	also	occurs	among	persons	without	T2DM	and	may	precede	
the	development	of	T2DM.2,3	Once	established,	T2DM	promotes	liver	
disease	progression	and	 is	an	 independent	 risk	 factor	 for	 liver	can-
cer.2	There	are	multiple	potential	common	pathogenic	mechanisms	in	
NAFLD	and	T2DM.	The	cascade	of	IR	leading	to	hyperinsulinaemia	and	
then	pancreatic	β-	cell	dysfunction	coupled	with	defective	 lipid	me-
tabolism	and	ensuing	hepatic	triglyceride	accumulation	are	described	
in	both	NAFLD	and	T2DM.4	Thus,	multiple	studies	have	evaluated	the	
role	of	insulin-	sensitizing	agents	as	treatment	for	NAFLD.5	However,	
improving	 IR	alone	does	not	appear	sufficient	 to	 resolve	NAFLD.6,7 
One	speculative	explanation	for	these	findings	might	be	that	despite	
improvement	in	 insulin	sensitivity,	pancreatic	β-	cell	function	contin-
ues	 to	deteriorate	and	 thus	 targeting	 insulin	 sensitivity	alone	has	a	
null	 effect.	 Recent	 data	 demonstrate	 that	 biopsy-	proven	NAFLD	 is	
associated	with	an	exaggerated	pancreatic	β-	cell	response.8	However,	
clinical	 imaging-	based	NAFLD	studies	have	 failed	 to	demonstrate	a	
relationship	 between	 NAFLD	 and	 pancreatic	 β-	cell	 dysfunction.9,10 
There	 are	 a	 lack	 of	 population-	level	 studies	 examining	 changes	 in	
pancreatic	β-	cell	response	to	blood	glucose	concentration	throughout	
adulthood	in	relation	to	changes	in	IR	on	NAFLD	and	T2DM.
Surrogate	 indicators	 for	 IR,	 as	 well	 as	 pancreatic	 β-	cell	 re-
sponse	to	glucose	concentration,	can	be	extrapolated	from	fasting	
blood	 glucose	 and	 insulin	 levels	 that	 are	 commonly	 included	 in	
population-	based	 studies.	 The	 homeostatic	 model	 assessments	
(HOMA)	are	simple	methods	for	estimating	β-	cell	response	to	glu-
cose	 concentration	 and	 how	well	 insulin	 is	 utilized	 by	 its	 target	
cell	populations.11	Specifically,	HOMA-	IR	 is	a	measure	 for	whole	
body	 IR	and	HOMA-	β	 is	a	measure	of	pancreatic	β-	cell	 response	
to	glucose	concentration.11	High	HOMA-	IR	equates	to	high	levels	
of	tissue	IR	and	high	HOMA-	β	equates	to	high	β-	cell	response.	We	
sought	to	characterize	temporal	trends	in	HOMA-	IR	and	HOMA-	β 
during	 young	 adulthood	 in	 relation	 to	 prevalent	 NAFLD	 in	mid-
dle	adulthood	and	subsequent	risk	of	T2DM	among	persons	with	
NAFLD.
[16%];	 moderate-	decreasing	 [63%];	 and	 high-	decreasing	 [21%]).	 Y25	 non-	alcoholic	
fatty	 liver	disease	prevalence	was	24.5%.	Among	non-	alcoholic	 fatty	 liver	disease,	
high-	increasing	 homeostatic	 model	 assessment	 insulin	 resistance	 (referent:	 low-	
stable)	was	associated	with	greater	prevalent	(OR	95%	CI	=	8.0,	2.0-	31.9)	and	incident	
(OR	=	10.5,	2.6-	32.8)	diabetes	after	multivariable	adjustment	including	Y0	or	Y25	ho-
meostatic	model	assessment	insulin	resistance.	In	contrast,	non-	alcoholic	fatty	liver	
disease	participants	with	low-	decreasing	homeostatic	model	assessment-	β	(referent:	
high-	decreasing)	had	the	highest	odds	of	prevalent	(OR	=	14.1,	3.9-	50.9)	and	incident	
(OR	=	10.3,	2.7-	39.3)	diabetes.
Conclusion:	Trajectories	of	 insulin	resistance	and	β-	cell	response	during	young	and	
middle	 adulthood	 are	 robustly	 associated	with	 diabetes	 risk	 in	 non-	alcoholic	 fatty	
liver	disease.	Thus,	how	persons	with	non-	alcoholic	fatty	liver	disease	develop	resist-
ance	to	insulin	provides	important	information	about	risk	of	diabetes	in	midlife	above	
and	beyond	degree	of	insulin	resistance	at	the	time	of	non-	alcoholic	fatty	liver	disease	
assessment.
K E Y W O R D S
coronary	artery	risk	development	in	young	adults,	non-alcoholic	fatty	liver	disease,	non-
alcoholic	steatohepatitis,	obesity
Key Points
•	 In	NAFLD,	presence	of	diabetes	 increases	risk	for	 liver	
disease	progression.
•	 Early	identification	of	risk	factors	for	diabetes	is	an	im-
portant	strategy	to	improve	outcomes	in	NAFLD.
•	 Increasing	insulin	resistance	from	young	adulthood	into	
middle	 age	 is	 associated	 with	 greatest	 risk	 of	 NAFLD	
and	subsequent	diabetes.
•	 Thus,	 how	 insulin	 resistance	 develops	 in	 NAFLD	 pro-
vides	important	information	about	risk	of	diabetes	inde-
pendent	of	degree	of	insulin	resistance	in	middle	age.
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2  | METHODS
2.1 | Study sample
The	Coronary	Artery	Risk	Development	in	Young	Adults	(CARDIA)	
study	is	an	ongoing	longitudinal	cohort	study	that	enrolled	5115	
black	and	white	men	and	women	18-	30	years	of	age	from	4	U.S.	
field	centres.	The	baseline	exam	(1985-	1986;	year	0,	Y0)	and	fol-
low-	up	 exams	 at	 2,	 5,	 7,	 10,	 15,	 20	 and	 25	years	 after	 baseline	
included	 extensive	 collection	 of	 detailed	 clinical	 data,	 includ-
ing	 non-	contrast	 computed	 tomography	 (CT)	 measurement	 of	
liver	fat	at	Y25.	Retention	rates	among	survivors	have	been	high	
throughout	the	study	with	>90%	of	the	surviving	cohort	maintain-
ing	contact.12	Participants	provided	written	informed	consent	at	
each	examination,	and	institutional	review	boards	from	each	field	
centre	 (University	 of	 Alabama	 at	 Birmingham,	 Birmingham,	 AL;	
Northwestern	 University,	 Chicago,	 IL;	 University	 of	 Minnesota,	
Minneapolis,	MN;	and	Kaiser	Permanente,	Oakland,	CA)	approved	
the	study	annually.
Fasting	glucose	and	insulin	were	measured	at	Y0,	Y7,	Y10,	Y15,	
Y20,	 and	 Y25.	 Measures	 at	 examinations	 when	 the	 participant	
was	pregnant	were	excluded	(n	=	192).	Measures	at	examinations	
when	the	participant	reported	taking	exogenous	insulin	were	ex-
cluded	 for	 calculation	 of	 HOMA-	β	 (n	=	29).11,13	 Of	 3060	 partic-
ipants	 with	 fasting	measures	 at	 Y0	 and	 at	 3	 or	 more	 follow-	up	
examinations,	 2455	 had	 liver	 fat	 assessed	 at	 Y25.	 Participants	
were	then	excluded	if	they	had	a	self-	reported	history	of	cirrhosis,	
hepatitis	(n	=	38),	a	risk	factor	for	chronic	liver	disease	(eg,	intra-
venous	drug	use,	n	=	52)	or	secondary	hepatic	 steatosis:	alcohol	
consumption	>14	standard	drinks/week	in	women	and	>21	stan-
dard	 drinks/week	 in	 men	 (n	=	225),7	 human	 immunodeficiency	
virus	 (n	=	14),	 and	medications	 (eg,	 valproic	 acid,	 methotrexate,	
tamoxifen	 and/or	 amiodarone;	 n	=	22).	 The	 remaining	2104	par-
ticipants	 formed	 the	 NAFLD-	eligible	 sample	 population	 for	 the	
HOMA-	IR	analyses.	For	HOMA-	β	analyses,	the	sample	was	2089	
because	of	15	participants	who	had	 reported	exogenous	 insulin	
use	that	resulted	in	less	than	three	repeated	fasting	insulin	mea-
sures	over	time	(Figure	S1).
2.2 | Measurements
Standardized	protocols	 for	data	collection	were	used	across	study	
centres	and	have	previously	been	described.12,14	Blood	was	drawn	
after	 a	 12-	hour	 fast	 in	 the	 seated	 position,	 separated	 and	 plasma	
frozen	to	−70°C	prior	to	analysis	 in	a	central	 laboratory.12 Glucose 
was	 assayed	 at	 Y0	with	 the	 hexokinase	 UV	method	 by	 American	
Bio-	Science	Laboratories	(Van	Nuys,	CA)	and	by	hexokinase	coupled	
to	glucose-	6-	phosphate	dehydrogenase	 (Merck	Millipore,	Billerica,	
MA)	at	Y7,	Y10,	Y15,	Y20	and	Y25.	Insulin	measurements	were	de-
termined	by	radioimmunoassay	(Linco	Research,	St.	Charles,	MO)	at	
Y0,	Y7,	Y10,	Y15	and	Y20,	as	well	as	by	an	Elecsys	sandwich	immuno-
assay	(Roche	Diagnostics,	Rotkreuz,	Switzerland)	at	Y25.	HOMA-	IR,	
HOMA-	β	were	calculated	as:	
where	FPI	is	fasting	plasma	insulin	concentration	(μU/L)	and	FPG	is	
fasting	plasma	glucose	(mmol/L).11,13
The	 presence	 of	 T2DM	 was	 assessed	 at	 each	 examination	
based	on	a	combination	of	medication	use	 for	T2DM	(every	exam-
ination),	 FPG	≥126	mg/dL	 (Y0,	Y7,	Y10,	Y15,	Y20	and	Y25),	 2-	hour	
glucose	≥200	mg/dL	 (Y10,	Y20	and	Y25)	by	OGTT,	or	haemoglobin	
A1c	 (HbA1c)	 ≥6.5%	 (Y20	and	Y25).	Prevalent	T2DM	was	defined	as	
meeting	T2DM	criteria	at	Y25	only	and	incident	T2DM	was	defined	
as	meeting	T2DM	criteria	at	any	exam	year	 (0,	7,	10,	15,	20	or	25),	
thus	incidence	is	greater	than	prevalence.
The	CT	protocol	 included	 the	heart	 and	 abdomen	using	 a	 non-	
contrast	 CT	 scan	 performed	 using	 GE	 (GE	 750HD	 64	 and	 GE	
LightSpeed	VCT	64,	Birmingham	and	Oakland	Centers,	respectively;	
GE	Healthcare,	Waukesha,	WI)	or	Siemens	(Sensation	64,	Chicago	and	
Minneapolis	Centers;	Siemens	Medical	Solutions,	Erlangen,	Germany)	
multidetector	 CT	 scanners	 and	 has	 been	 described	 previously.15 
Quality	control	and	image	analysis	was	performed	at	a	core	reading	
centre	(Wake	Forest	University	Health	Sciences,	Winston-	Salem,	NC).	
Any	(eg,	Mild-	Moderate-	Severe)	NAFLD	was	defined	as	liver	attenu-
ation	(LA)	<51	Hounsfield	Units	(HU,	equivalent	to	a	liver/spleen	ratio	
HOMA- IR= (FPI×FPG)∕22.5,
HOMA- β= (20×FPI)∕(FPG−3.5),
F IGURE  1 Trajectories	by	Age	in	the	Coronary	Artery	Risk	
Development	in	Young	Adults	(CARDIA)	Study	of	A,	HOMA-	IR	and	
B,	HOMA-	β
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<1)16	 and	moderate-	severe	NAFLD	 as	 a	 LA	 ≤40	HU	 (equivalent	 to	
≥30%	liver	fat)	after	exclusion	of	other	liver	fat	causes.15
2.3 | Statistical analysis
Group-	based	 trajectory	modelling	was	used	 to	 identify	 and	 cat-
egorize	participants	based	on	patterns	of	 longitudinal	 change	 in	
HOMA-	IR	or	HOMA-	β	during	the	25	years	of	follow-	up	(N	=	3060	
for	HOMA-	IR,	N	=	3031	for	HOMA-	β).17	HOMA-	IR	and	HOMA-	β 
were	 logarithmically	 transformed	 to	 approximate	 normality.	
Models	 were	 fit	 using	 SAS	 Proc	 traj.18	 Group-	based	 trajectory	
analysis	 is	designed	 to	 identify	 clusters	of	 individuals	with	 simi-
lar	patterns	of	 change	over	 time.	The	optimal	number	of	 trajec-
tory	 classes	 was	 determined	 using	 the	 Bayesian	 information	
criterion	such	that	no	group	included	less	than	5%	of	participants.	
Participants	were	assigned	to	the	trajectory	group	for	which	they	
had	 the	 greatest	 posterior	 predictive	 probability.17	 Trajectory	
groups	were	then	qualitatively	examined	and	named	to	describe	
the	visual	pattern	of	change.	To	estimate	the	association	of	trajec-
tory	group	with	prevalent	NAFLD	or	T2DM	in	NAFLD,	trajectory	
group	was	included	as	an	independent	variable	in	a	logistic	regres-
sion	model	examining	predictors	of	continuous	LA	or	any	NAFLD	
or	moderate-	severe	NAFLD	or	T2DM	 in	NAFLD	at	Y25.	Models	
were	sequentially	adjusted	a	priori	for	demographics	(age,	gender,	
race,	education,	centre),	cumulative	burden	of	metabolic	risk	fac-
tors	 (pack-	years	of	 smoking,	physical	activity	 [exercise	units	per	
year],	 alcohol	 use	 [drinks/week],	 systolic	 blood	 pressure	 [SBP],	
total/high	density	lipoprotein	cholesterol	[HDL-	C]	ratio	and	num-
ber	 of	 visits	with	 blood	 pressure	 or	 lipid-	lowering	medications),	
percent	 change	 in	 BMI	 relative	 to	 baseline,	 and	 HOMA-	IR	 or	
HOMA-	β	at	Y0	or	Y25.	Cumulative	SBP,	alcoholic	beverages,	phys-
ical	 activity	 and	 total-	HDL-	C	 ratio	 were	 calculated	 by	 summing	
the	 product	 of	 the	 average	 SBP	 (alcohol	 or	 physical	 activity	 or	
BMI	or	total/HDL-	C	ratio)	and	the	time	interval	(in	years)	between	
two	consecutive	examinations	over	the	25	years.	To	account	for	
hypoglycaemic	medication	use	over	time,	T2DM	medication	was	
included	 in	 the	 final	model	 (Model	3)	 as	a	dichotomous	variable	
at	 each	 exam	 year.	 Sensitivity	 analysis	 was	 also	 performed	 ex-
cluding	measures	from	participants	on	any	T2DM	medications	at	
any	exam	year.	 Interaction	terms	were	assessed	between	trajec-
tory	group	membership	and	race	and	sex.	 In	addition,	as	a	com-
parator	group	we	assessed	the	relationship	between	HOMA-	IR	or	
HOMA-	β	trajectory	groups	and	prevalent/incident	T2DM	among	
the	 1593	NAFLD-	eligible	 participants	with	 CT	 liver	 attenuation	
>51	HU	(eg,	non-	NAFLD)	in	CARDIA	(Figure	S1).
Finally,	 three	 mutually	 exclusive	 clusters	 were	 defined	 based	
on	 hypothesized	 β-	cell	 response	 and	 IR	 dynamics	 using	 observed	
HOMA-	IR	 and	 HOMA-	β	 trajectory	 group	 membership	 pair	 (eg,	
increasing	 IR	 promotes	 β-	cell	 demise	 and	 inhibits	 β-	cell	 compen-
sation,	Table	S2).	Adjusting	 for	 the	same	set	of	covariates,	 logistic	
regression	analyses	were	used	to	model	the	odds	of	having	NAFLD	
or	prevalent/incident	T2DM	among	NAFLD	participants	at	Y25	for	
each	cluster	in	separate	models.	All	analyses	were	completed	using	C
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SAS	software	version	9.4	(SAS	Institute	Inc.,	Chicago,	IL).	Two-	sided	
P	<	.05	was	considered	statistically	significant.
3  | RESULTS
3.1 | HOMA- IR and HOMA- β trajectories
Three	discrete	 trajectories	 in	HOMA-	IR	and	HOMA-	β	 from	young	
adulthood	to	middle	age	were	identified	(Figure	1).	Both	HOMA-	IR	
(Figure	1A)	and	HOMA-	β	 (Figure	1B)	tracked	over	time	among	par-
ticipants.	For	IR,	nearly	half	of	the	cohort	(n	=	1429,	47%)	maintained	
fairly	stable	low	IR	throughout	follow-	up	(low-	stable)	whereas	42%	
(n	=	1285)	 had	moderate	 increase	 in	 IR	 (moderate-	increasing)	 and	
12%	(n	=	346)	had	high	increase	in	IR	(high-	increasing).	For	HOMA-	β,	
all	 trajectory	 groups	 demonstrated	 a	 decrease	 in	 HOMA-	β	 after	
age	 45	 (Figure	1B).	 However,	 the	 majority	 of	 participants	 main-
tained	 fairly	 HOMA-	β	 throughout	most	 of	 young	 adulthood:	 21%	
(n	=	626)	 had	 high-	decreasing	 HOMA-	β	 and	 63%	 (n	=	1917)	 had	
moderate-	decreasing	HOMA-	β.	Only	16%	(n	=	488)	of	participants	
demonstrated	a	notable	early	 and	 sustained	decrease	 in	HOMA-	β 
throughout	young	adulthood	(eg,	low-	decreasing).
Participant	 characteristics	 at	 Y0	 according	 to	 HOMA	 tra-
jectory	 group	 are	 presented	 in	 Table	1.	 Individuals	 with	 high-	
decreasing	 HOMA-	β	 were	 older	 and	 predominantly	 women	 and	
black.	 Individuals	with	 high-	decreasing	HOMA-	β	 were	more	 likely	
to	be	overweight	or	obese	compared	to	individuals	with	moderate-	
decreasing	and	low-	decreasing	HOMA-	β.	Similarly,	individuals	with	
high-	increasing	 HOMA-	IR	 were	 predominantly	 women,	 black	 and	
had	higher	 baseline	BMI	 compared	 to	 the	 low-	stable	 IR	 group.	At	
Y25,	 participants	 with	 moderate-	decreasing	 and	 high-	decreasing	
HOMA-	β	 were	 more	 likely	 to	 display	 features	 of	 the	 metabolic	
syndrome	 compared	 to	 participants	 in	 the	 low-	decreasing	 group	
(Table	2).	 Similar	 trends	were	 seen	 in	 participants	with	moderate-	
increasing	or	high-	increasing	IR	throughout	adulthood	compared	to	
participants	with	low-	stable	IR	(Table	2).
3.2 | HOMA trajectories and NAFLD
Non-	alcoholic	fatty	liver	disease	prevalence	in	CARDIA	was	24.5%	
and	 was	 higher	 with	 increasing	 HOMA-	IR	 group.	 Any	 NAFLD	
(eg,	 LA	<	51	HU)	was	 present	 in	 7.4%,	 32.5%,	 and	 63.6%	 in	 the	
low-	stable,	 moderate-	increasing	 and	 high-	increasing	 HOMA-	IR	
groups	respectively	 (P	 for	 trend	<.0001,	Figure	2A).	Within	each	
HOMA-	IR	group,	NAFLD	was	greater	in	whites	compared	to	blacks	
and	in	men	compared	to	women,	with	the	exception	of	the	high-	
increasing	HOMA-	IR	group	in	which	white	women	had	the	highest	
NAFLD	prevalence	(Figure	S2A).	There	was	no	significant	interac-
tion	by	 race	or	 gender	 in	 all	models	 and	 thus	pooled	 results	 are	
shown.
Table	3	 demonstrates	 the	 association	 between	 HOMA-	IR	
or	 HOMA-	β	 trajectory	 group	 and	 continuous	 LA	 or	 NAFLD.	 For	
HOMA-	IR,	those	in	trajectory	groups	with	patterns	of	 increasingly	
severe	 IR	 (referent:	 low-	stable)	 had	 progressively	 greater	 odds	 of	
having	 any	NAFLD	 after	 adjustment	 for	 demographic	 characteris-
tics	 and	 education	 (Table	3).	 These	 associations	 were	 moderately	
attenuated	when	adjusted	for	demographics,	cumulative	burden	of	
metabolic	risk	factors	and	Y0	HOMA-	IR.	Associations	were	attenu-
ated	more	substantially,	but	remained	statistically	significant	when	
adjusted	 for	 Y25	 HOMA-	IR.	 The	 association	 between	 HOMA-	IR	
trajectory	group	and	moderate-	severe	NAFLD	(n	events	=	224)	was	
similar	in	direction	and	magnitude	(Table	3).	Findings	were	also	sim-
ilar	for	continuous	LA.
Non-	alcoholic	fatty	liver	disease	prevalence	at	Y25	was	also	higher	
with	increasing	HOMA-	β	group,	with	NAFLD	present	in	14.3%,	21.3%	
and	40.8%	of	individuals	in	the	low-	decreasing,	moderate-	decreasing	
and	high-	decreasing	groups	respectively	(P	for	trend	<.0001,	Figure	2B).	
NAFLD	prevalence	increased	with	increasing	HOMA-	β	trajectory	in	all	
race,	gender	groups	with	the	exception	of	black	women	where	NAFLD	
prevalence	was	24.5%,	13.6%	and	29.3%	in	the	low,	moderate	and	high	
HOMA-	β	trajectory	groups	respectively	(Figure	S2B).
In	comparison	with	individuals	in	the	low-	decreasing	group,	those	
in	trajectory	groups	with	higher	HOMA-	β	had	progressively	greater	
odds	of	NAFLD	even	after	adjustment	 for	demographics	 (Table	3).	
These	associations	were	moderately	attenuated	when	adjusted	for	
F IGURE  2 Year	25	NAFLD*	Prevalence	stratified	by	A,	
HOMA-	IR	and	B,	HOMA-	β	Trajectory	Group.	Chi-	square	P	<	.0001	
for	trajectory	group	membership	for	both	HOMA	assessments.	
*NAFLD	defined	as	CT	liver	attenuation	<51	HU	after	exclusions	
for	other	causes	of	liver	fat
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cumulative	NAFLD	risk	factors,	including	Y0	HOMA-	β.	Associations	
were	attenuated	more	 substantially,	 but	 remained	 statistically	 sig-
nificant	when	adjusted	for	Y25	HOMA-	β.	The	association	between	
HOMA-	β	 trajectory	 and	 continuous	 LA	 and	 moderate-	severe	
NAFLD	 (n	 events	=	224)	 was	 similar	 in	 direction	 and	 magnitude	
(Table	3).	 In	 sensitivity	 analyses	 excluding	 those	 participants	 who	
were	 taking	T2DM	medications	 at	 any	 time	point,	 all	 associations	
were	unchanged	(data	not	shown).
3.3 | HOMA trajectories and T2DM among NAFLD 
participants
Among	 participants	 with	 any	 NAFLD	 (n	=	511),	 both	 prevalent	
and	 incident	 T2DM	 at	 Y25	 was	 higher	 with	 increasing	 HOMA-	IR	
(P	<	.0001,	Figure	3A).	In	contrast,	participants	with	low-	decreasing	
HOMA-	β	trajectory	had	the	highest	prevalence	of	T2DM	(P	<	.0001,	
Figure	3B).	 In	multivariable	 analysis,	 low-	decreasing	HOMA-	β	 (ref-
erent:	high-	decreasing)	trajectory	was	associated	with	higher	odds	
of	 prevalent	 (OR	=	11.8	 [4.3,	 32.4])	 and	 incident	 (OR	=	9.1	 [3.4,	
24.3])	 T2DM	 independent	 of	 cumulative	 T2DM	 risk	 factors	 and	
Y25	 HOMA-	IR	 (Table	4).	 In	 contrast,	 high-	increasing	 HOMA-	IR	
(referent:	low-	stable)	trajectory	was	associated	with	greater	preva-
lent	 (OR	=	4.6	 [1.1,	18.9])	and	 incident	 (OR	=	7.2	 [1.8,	29.2])	T2DM	
(Table	4).	 Findings	 were	 similar	 in	 direction	 though	 somewhat	
stronger	 in	 magnitude	 in	 both	 unadjusted	 and	 adjusted	 analyses	
among	non-	NAFLD	CARDIA	participants	who	were	excluded	from	
the	primary	analyses	(n	=	1593,	Table	S1).
3.4 | HOMA- IR and HOMA- β trajectory 
group clusters
The	prevalence	of	CARDIA	participants	in	each	HOMA-	IR/HOMA-	β 
trajectory	group	cluster	are	shown	in	Table	S2.	The	low	HOMA	IR-	low	
HOMA	β	cluster	and	high	HOMA	IR-	high	HOMA	β	cluster	contained	
45.7%	and	21.1%	of	participants	respectively.	The	remaining	partici-
pants	formed	the	referent	cluster	(n	=	1008,	33.2%).	Participants	in	
the	high	HOMA	IR-	high	HOMA	β	cluster	were	predominantly	black	
(61.4%)	 and	women	 (63.8%),	 and	participants	with	 low	HOMA	 IR-	
low	HOMA	β	cluster	were	predominantly	white	(67.2%)	and	women	
(57.5%).	Notably,	participants	 in	 the	high	HOMA	 IR-	high	HOMA	β 
cluster	had	the	lowest	education	and	physical	activity	level,	and	less	
favourable	levels	for	components	of	the	metabolic	syndrome	at	Y0	
(Table	S3)	and	at	Y25	(Table	S4).
Table	5	displays	the	odds	of	NAFLD	or	T2DM	among	NAFLD	
participants	at	Y25	for	the	3	HOMA	IR-	HOMA	β	trajectory	group	
clusters.	The	odds	of	NAFLD	were	significantly	higher	in	the	high	
HOMA	 IR-	high	 HOMA	 β	 cluster	 than	 the	 referent	 cluster	 in	 all	
models.	When	IR	and	β-	cell	response	trajectories	were	both	high,	
the	odds	of	developing	NAFLD	were	significantly	higher	than	the	
referent.	In	contrast,	participants	in	the	low	HOMA	IR-	low	HOMA	
β	cluster	had	significantly	lower	odds	of	NAFLD	compared	to	the	
referent.	 In	 terms	of	T2DM	risk,	NAFLD	participants	 in	 the	high	
HOMA	 IR-	high	HOMA	β	 cluster	 had	 significantly	higher	odds	of	
both	prevalent	and	incident	T2DM	in	the	base	model,	but	associ-
ations	were	attenuated	and	no	 longer	 significant	 in	 the	 fully	ad-
justed	model.
4  | DISCUSSION
In	this	population-	based	prospective	study	of	black	and	white	adults	
followed	up	for	25	years,	we	identified	three	distinct	trajectories	of	
IR	and	pancreatic	β-	cell	 response	to	glucose,	separately.	These	tra-
jectories	were	independently	associated	with	prevalent	NAFLD	and	
T2DM	among	individuals	with	NAFLD	in	midlife.	We	found	that	those	
groups	with	 greater	 IR	 increase	 from	young	 adulthood	 into	middle	
age	have	the	greatest	odds	of	having	NAFLD	and	subsequent	T2DM,	
regardless	of	demographics,	cumulative	burden	of	metabolic	covari-
ates,	and	degree	of	IR	at	Y0	or	concurrently	at	Y25.	Higher	β-	cell	re-
sponse,	was	also	related	to	higher	odds	of	NAFLD,	however,	 lower	
β-	cell	 response,	was	 related	 to	higher	odds	of	T2DM.	When	 taken	
F IGURE  3 Year	25	Prevalent	and	Incident	Diabetes	among	
persons	with	NAFLD*	stratified	by	A,	HOMA-	IR	and	B,	HOMA-	β 
Trajectory	Group.	Chi-	square	P	<	.0001	for	trajectory	group	
membership	for	both	HOMA	assessments.	*NAFLD	defined	as	CT	
liver	attenuation	<51	HU	after	exclusions	for	other	causes	of	liver	
fat.	Estimates	are	for	participants	with	diabetes	by	Y25	follow-	up,	
not	at	Y25	follow-	up,	thus	incidence	is	>prevalence
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collectively,	 persons	 with	 high	 β-	cell	 response,	 in	 relation	 to	 high	
IR	had	 the	highest	odds	of	 prevalent	NAFLD	and	T2DM	 in	midlife	
independent	 of	 cumulative	metabolic	 confounders.	 These	 findings	
highlight	 early	 identification	 of	 increasing	 IR	 and	 pancreatic	 β-	cell	
response	 to	glucose,	as	potential	 targets	 for	primary	prevention	of	
NAFLD	and	T2DM	in	NAFLD.
Multiple	studies	have	demonstrated	hyperinsulinaemia,	and	thus	
elevated	HOMA-	IR,	 in	NAFLD.19	 IR	 is	 inadequate	 response	by	 tis-
sues	to	the	physiological	effects	of	insulin.	IR	is	thus	tissue-	specific.	
HOMA-	IR	typically	reflects	hepatic	 IR.20	However,	the	 liver	 is	also	
the	 primary	 site	 of	 insulin	 clearance	 in	 humans.21	 Several	 studies	
have	shown	that	HOMA-	IR	elevation	in	NAFLD	is	primarily	related	
to	 impaired	 hepatic	 insulin	 clearance	 rather	 than	 impaired	 insulin	
suppression	of	hepatic	glucose	production.1,22	Thus,	HOMA-	IR	may	
be	a	poor	overall	marker	of	hepatic	IR	in	NAFLD	and	the	relationship	
between	glucose	and	 insulin	 is	 impaired	 in	 these	patients.	 In	 con-
trast,	adipose	IR	may	be	an	important	driver	of	NAFLD	pathogene-
sis:	dysfunctional	adipose	tissue	→	increase	in	circulating	free	fatty	
acids	→	hepatic	steatosis	(eg,	lipotoxicity).22,23	Therefore,	in	NAFLD,	
HOMA-	IR	may	be	a	risk marker	for	underlying	dysfunctional	adipose	
tissue	and	may	not	necessarily	correlate	with	hepatic	IR.	Direct	mea-
sures	of	adipose	tissue	IR	would	add	strength	to	our	study	but	are	
not	available.
We	also	demonstrate	 that	 high	pancreatic	β-	cell	 response	 to	
glucose	throughout	adulthood	is	a	marker	of	NAFLD	independent	
of	metabolic	 risk	 factors.	 Previous	 studies	 likewise	 demonstrate	
that	liver	fat	is	associated	with	absolute	increases	in	insulin	secre-
tion	 from	 the	β-	cell,	 in	order	 to	compensate	 for	 IR	and	maintain	
euglycemia.24	 It	 has	 also	 been	 demonstrated	 that	 NAFLD	 is	 as-
sociated	with	pancreatic	β-	cell	dysfunction	in	non-	diabetic	obese	
subjects.8,9	NAFLD	individuals	have	an	exaggerated	β-	cell	 insulin	
secretory	 response	 to	 an	oral	 glucose	 load	 independent	of	BMI,	
age	and	sex;	and	a	decline	in	β-	cell	 index,	which	reflects	pancre-
atic	β-	cell	function,	in	the	setting	of	underlying	IR.8,23	Our	current	
findings	 add	 to	 the	 epidemiological	 evidence	 that	 increasing	 IR	
and	pancreatic	β-	cell	 response	 to	 glucose	 are	markers	 of	 under-
lying	metabolic	disarray	that	predisposes	to	risk	for	T2DM	in	per-
sons	with	both	NAFLD	and	non-	NAFLD.	However,	it	is	important	
to	note	that	similar	to	HOMA-	IR,	HOMA-	β	is	also	affected	by	de-
gree	of	hepatic	insulin	clearance,	which	is	proportional	to	hepatic	
TABLE  4 Prevalent	or	incident	type	2	diabetes	mellitus	according	to	HOMA-	β	or	HOMA-	IR	trajectory	group	among	511	participants	with	
prevalent	NAFLD	at	the	year	25	exam,	the	coronary	artery	risk	development	in	young	adults	study	(1985-	1986	to	2010-	2011)
Prevalent Y25 T2DM 
N events/total N = 136/511a
OR (95% CI)
Incident Y25 T2DM 
N events/total N = 144/508a
OR (95% CI)
Nd Model 1 Model 2 Model 3 Nd Model 1 Model 2 Model 3
HOMA-	IR	trajectoryb
Low-	stable 3/72 Reference 3/72 Reference
Moderate-	
increasing
42/290 3.1	(0.91,	10.3) 1.7	(0.48,	6.2) 1.2	(0.32,	4.4) 47/289 3.6*	(1.1,	12.0) 2.2	(0.62,	8.1) 1.7	(0.46,	6.2)
High-	
increasing
91/149 31.6‡	(9.3,	107.3) 8.0‡	(2.0,	31.9) 4.6*	(1.1,	18.9) 94/147 36.3‡	(10.7,123.4) 10.5‡	(2.6,	42.8) 7.2§	(1.8,	29.2)
HOMA-	β	trajectoryc
Low-	
decreasing
27/48 9.4‡	(4.1,	21.5) 14.1‡	(3.9,	50.9) 11.8‡	(4.3,	32.4) 27/48 7.2‡	(3.2,	16.2) 10.3‡	(2.7,	39.3) 9.1‡	(3.4,	24.3)
Moderate-	
decreasing
58/282 1.1	(0.70,	1.8) 1.6	(0.79,	3.2) 1.5	(0.92,	2.9) 63/282 1.0	(0.64,	1.6) 1.3	(0.62,	2.6) 1.7	(0.94,	2.9)
High-	
decreasing
46/176 Reference 52/176 Reference
BMI,	body	mass	index;	CI,	confidence	interval;	HDL,	high	density	lipoprotein;	HOMA,	homeostatic	model	assessment;	IR,	insulin	resistance;	NAFLD,	
nonalcoholic	fatty	liver	disease;	OR,	odds	ratio;	T2DM,	type	2	diabetes	mellitus;	TC,	total	cholesterol;	Y25,	year	25	follow-	up	exam.
NAFLD	=	liver	attenuation	<51	HU	after	exclusion	for	secondary	cause	of	liver	fat.
Results	presented	as	Odds	Ratio	(95%	Confidence	Interval).
aTotal	N	=	506	for	analyses	with	HOMA-	β	after	exclusion	of	participants	with	exogenous	insulin	use.
Model	1:	Age,	gender,	race,	field	center,	educational	attainment		Model	2:	Model	1	+	pack-	years	smoking	exposure,	cumulative	alcohol	use	(drinks/d),	
physical	activity	level	(exercise	units-	year),	cumulative	systolic	blood	pressure	(mm	Hg-	years),	number	of	years	with	blood	pressure	or	lipid-	lowering	
medications,	cumulative	TC/HDL	ratio,	diabetes	medications	(at	each	exam	year),	%change	BMI	and	baseline	HOMA-	IRb	HOMA-	βc		Model	3:	Model	
1	+	pack-	years	 smoking	exposure,	 cumulative	 alcohol	 use	 (drinks/d),	 physical	 activity	 level	 (exercise	units-	year),	 cumulative	 systolicblood	pressure	
(mm	Hg-	years),	number	of	years	with	blood	pressure	or	lipid-	lowering	medications,	cumulative	TC/HDL	ratio,	diabetes	medications	(at	each	exam	year),	
%change	BMI	and	Y25	HOMA-	IRb	HOMA-	βc.
dNumber	of	participants	with	diabetes	over	the	total	number	of	NAFLD	participants	in	each	trajectory	group.
‡P	<	.001	compared	with	the	referent	group.
§P	<	.01	compared	with	the	referent	group.
*P	<	.05	compared	to	Low	group.
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fat	content.	Thus,	HOMA-	β	may	be	a	poor	overall	marker	of	pan-
creatic	β-	cell	function	in	NAFLD.	Prospective	studies	that	assess	
rate	of	change	 in	hepatic	 insulin	clearance	over	 time	are	needed	
to	 fully	understand	the	role	of	 IR	and	pancreatic	β-	cell	 response	
during	NAFLD	development.
Progression	to	diabetes	is	a	complex	interplay	among	IR,	 in-
sulin	 sensitivity,	 and	 pancreatic	 β-	cell	 function.	 A	 decrease	 in	
sensitivity	 to	 insulin	demands	 compensation	 through	a	propor-
tionate	 adjustment	 in	 insulin	 secretion	 by	 pancreatic	 β-	cells	 to	
maintain	 glucose	 homeostasis.25	 On	 a	 population-	level,	 T2DM	
risk	 is	 driven	 by	multiple	 factors.	We	 have	 now	 demonstrated	
among	persons	with	both	NAFLD	and	non-	NAFLD	that	increas-
ing	level	of	IR	over	time	is	an	important	driver	in	the	risk	of	sub-
sequent	T2DM.	In	addition,	we	found	that	high	IR	and	high	β-	cell	
response	in	participants	with	NAFLD	increased	odds	of	incident	
T2DM	by	30%	compared	 to	participants	with	NAFLD	and	high	
IR and low β-	cell	response.	 In	contrast,	 low	IR	despite	 low	pan-
creatic	 β-	cell	 response	 was	 associated	 with	 a	 36%	 decreased	
odds	of	T2DM	suggesting	that	IR	is	the	primary	driver	of	T2DM	
in	 NAFLD.	 Once	 established,	 T2DM	may	 promote	 progression	
to	 NASH,	 cirrhosis	 and	 hepatocellular	 carcinoma.2	 Thus,	 im-
proved	understanding	of	risk	factors	for	development	of	T2DM	
in	NAFLD	is	critical	in	order	to	target	prevention	of	liver	disease	
progression.
Several	 limitations	 should	 also	 be	 considered	when	 interpret-
ing	our	results.	CT	is	a	relatively	insensitive	measure	of	hepatic	fat	
when	compared	with	magnetic	resonance	imaging,16,26	which	may	
bias	our	results	toward	the	null	and	underestimate	the	strength	of	
the	observed	association.	NAFLD	was	also	not	assessed	in	CARDIA	
prior	to	the	Y25	follow	up	examination	and	thus,	we	cannot	estab-
lish	temporality	of	our	HOMA-	IR	and	HOMA-	β	trajectories	or	inci-
dent	diabetes	in	relation	to	NAFLD	onset.	However,	since	NAFLD	
is	primarily	 an	asymptomatic	disease,	detection	 in	midlife	mirrors	
clinical	 practice	when	NAFLD	 is	 commonly	 incidentally	 found	 on	
imaging	performed	for	other	reasons.27	It	is	also	possible	that	some	
CARDIA	participants	had	undiagnosed	NAFLD	at	Y0.	However,	62%	
of	NAFLD	participants	were	normal	weight	at	Y0	and	only	10%	had	
obesity.	 Since	 undiagnosed	NAFLD	may	 have	 been	 present	 early	
in	follow	up,	we	also	cannot	rule	out	the	possibility	of	reverse	cau-
sality	(eg,	NAFLD	causing	an	increase	in	IR,	rather	than	vice	versa).	
CARDIA	only	 included	whites	 and	 blacks	 and	 did	 not	 specifically	
ask	about	ethnicity.	Thus,	we	cannot	generalize	our	findings	to	the	
Hispanic	 population	 wherein	 NAFLD	 and	 T2DM	 are	 exceedingly	
high.	The	assays	for	glucose	and	insulin	changed	during	the	25-	year	
follow-	up	because	of	technological	advances.	However,	83%	of	the	
measurements	were	assessed	using	 the	same	method.	Finally,	we	
employed	surrogate	markers	of	IR	and	β-	cell	response	and	did	not	
use	 repeated	OGTT	 or	 frequent	 sampling	 of	 intravenous	 glucose	
tolerance	 test	 or	 c-	peptide	 levels	 to	measure	 IR	 or	 pancreatic	 β-	
cell	 function.	Thus,	we	cannot	directly	 relate	 insulin	 resistance	to	
insulin	secretion	within	an	individual.	We	are	also	unable	to	assess	
effect	of	degree	of	hepatic	 insulin	clearance	on	absolute	 levels	of	
HOMA-	IR	or	HOMA-	β.	However,	HOMA	models	can	be	easily	cal-
culated	 in	 clinical	 practice	 and	 thus	 temporal	 trends	 (rather	 than	
absolute	 levels)	may	be	useful	for	detection	of	NAFLD	individuals	
at	high	risk	for	T2DM.
TABLE  5 Relationship	between	HOMA-	β	and	HOMA-	IR	
trajectory	group	clusters	in	relation	to	risk	of	Y25	NAFLDa and 
prevalent	or	incident	type	2	diabetes	among	NAFLD	participants
OR (95% CI)
Base model
Multivariable 
model
Prevalent	NAFLDa Nb
Referent	
clusterc
209/685 1.00 1.00
High	IR-	high	β 
clusterd
215/445 3.44	(2.59,	4.6)‡ 2.48	(1.81,	3.41)‡
Low	IR-	low	β 
clustere
82/959 0.18	(0.13,	0.24)‡ 0.34	(0.25,	0.48)‡
Prevalent	T2DM	in	
NAFLD
Nf
Referent	
clusterc
42/209 1.00 1.00
High	IR-	high	β 
clusterd
78/215 1.75	(1.09,	2.81)§ 1.53	(0.66,	3.55)
Low	IR-	Low	β 
Clustere
11/82 0.79	(0.37,	1.68) 0.98	(0.55,	1.73)
Incident	T2DM	in	
NAFLD
Nf
Referent	
clusterc
46/209 1.00 1.00
High	IR-	high	β 
clusterd
85/215 1.79	(1.12,	2.85)§ 1.01	(0.58,	1.76)
Low	IR-	low	β 
clustere
11/82 0.72	(0.34,	1.53) 0.88	(0.44,	1.76)
BMI,	body	mass	 index;	CI,	confidence	 interval;	HDL,	high	density	 lipo-
protein;	HOMA,	homeostatic	model	assessment;	 IR,	 insulin	 resistance;	
NAFLD,	nonalcoholic	fatty	liver	disease;	OR,	odds	ratio;	T2DM,	type	2	
diabetes	mellitus;	TC,	total	cholesterol;	Y25,	year	25	follow-	up	exam.
Base	model:	Age,	gender,	race,	field	center,	educational	attainment.
Multivariable	Model:	Base	model	+	pack-	years	smoking	exposure,	cumu-
lative	alcohol	use	(drinks/d),	physical	activity	level	(exercise	units-	year),	
cumulative	systolic	blood	pressure	(mm	Hg-	years),	number	of	years	with	
blood	pressure	or	lipid-	lowering	medications,	cumulative	TC/HDL	ratio,	
diabetes	medications	(at	each	exam	year),	%change	BMI,	Y25	HOMA-	IR	
and	Y25	HOMA-	β.
aNAFLD	=	liver	attenuation	<51	HU	after	exclusion	for	secondary	cause	
of	liver	fat.
bNumber	of	participants	with	NAFLD	over	the	total	number	of	NAFLD-	
eligible	participants	(n	=	2089)	assessed	at	the	year	25	follow-	up	exam	in	
each	trajectory	group	pair.
cReferent	 Cluster	=	high	 HOMA-	IR	 and	 low	 HOMA-	β,	 moderate	
HOMA-	IR	and	moderate	HOMA-	β	or	low	HOMA-	IR	and	high	HOMA-	β.
dHigh	IR-	High	β	cluster	=	high	HOMA-	IR	and	high	HOMA-	β,	high	HOMA-	IR	
and	moderate	HOMA-	β	or	moderate	HOMA-	IR	and	high	HOMA-	β.
eLow	IR-	Low	β	cluster	=	low	HOMA	IR	and	low	HOMA-	β,	low	HOMA-	IR	
and	moderate	HOMA-	β,	or	moderate	HOMA-	IR	and	low	HOMA-	β.
fNumber	of	participants	with	T2DM	over	the	total	number	of	NAFLD	partic-
ipants	(n	=	506)	at	the	year	25	follow-	up	exam	in	each	trajectory	group	pair.
‡P	<	.001	compared	with	the	referent	group.
§P	<	.01	compared	with	the	referent	group.
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4.1 | Potential clinical implications
Higher	IR	is	a	well-	known	risk	factor	for	the	development	of	NAFLD	
and	T2DM	and	β-	cell	failure	is	a	known	requirement	for	the	develop-
ment	of	T2DM	 in	 IR	patients.	However,	our	 findings	 suggest	 than	
an	individual’s	long-	term	pattern	of	change	in	insulin	sensitivity	and	
secretion	starting	in	early	adulthood	provides	additional	information	
about	their	risk	for	the	development	of	NAFLD	and	T2DM	in	midlife	
independent	of	absolute	level	of	insulin	resistance	or	β-	cell	response	
in	early	adulthood	or	 in	midlife.	 In	 the	age	of	 the	electronic	medi-
cal	 record,	 repeated	measures	 of	 insulin	 sensitivity	 and	 secretion	
throughout	adulthood	can	be	readily	graphed	allowing	clinicians	to	
recognize	at-	risk	patterns	 (eg,	 rapidly	 rising	 IR)	early	 in	adulthood.	
Early	 identification	of	young	adults	with	high	HOMA-	IR	trajectory	
may	 lead	 to	 treatments	 that	 target	 prevention	 of	 adipose	 tissue	
overload	(eg,	weight	maintenance,	physical	activity)	and	prevention	
of	adipose	tissue	insulin	signalling	inactivation	(eg,	pioglitazone)	for	
primary	prevention	of	NAFLD.	The	potential	clinical	implications	of	
our	findings	require	further	prospective	study.
5  | CONCLUSION
Trajectories	of	IR	and	pancreatic	β-	cell	response	to	glucose	concen-
tration	throughout	early	adulthood	to	middle	age—independent	of	
baseline	 and	 concurrent	 IR	 and	 β-	cell	 response—may	 provide	 ad-
ditional	 information	about	the	cumulative	burden	of	 IR	and	risk	of	
prevalent	 NAFLD	 and	 T2DM	 in	 midlife.	 These	 associations	 were	
independent	 of	 key	 comorbidities	 and	metabolic	 risk	 factors.	 This	
novel	characterization	of	the	relationship	between	IR	and	β-	cell	re-
sponse	trajectories	across	young	adulthood	highlights	this	age	period	
as	an	important	time	to	target	behaviour	and	lifestyle	interventions	
for	primordial	prevention	of	NAFLD	and	subsequent	T2DM.
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